DiCE Places Bets On Tomorrow's Small Molecules
Executive Summary
Emerging Company Profile: New technology platform aims to apply directed evolution to identify small molecule candidates, much like large molecules like monoclonal antibodies are developed, which the Calif. start-up thinks can bring oral drugs to new fields.
You may also be interested in...
Finance Watch: Venture Capital, Debt Financings Led Fundraising Surge In Q2
New VC deals include a $60m series C-1 round for DiCE Molecules a day before it filed paperwork to support a $100m IPO and a $100m financing for China’s IONOVA Life Science. Also, RenovoRx was the 84th company to go public in the US this year and ADC Therapeutics executed a $325m royalty deal.
Finance Watch: Scorpion Closes $162m Series B, Bringing Recent Total To $270m
Private Company Edition: The pre-J.P. Morgan Healthcare Conference financing news deluge during the first week of 2021 included several significant venture capital deals, including a $226m series B round for Affinivax, Ikena’s $120m series B round and an $88m series A round for Aro.